文献速递肿瘤 PET/CT核素与放射性配体治疗

基于PSMA PET/CT的全身肿瘤负荷视觉分类预测转移性激素敏感性前列腺癌患者对新型雄激素受体信号抑制剂的反应

A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-25

该研究纳入165例初诊转移性激素敏感性前列腺癌(mHSPC)患者,基于[18F]F-PSMA PET/CT提出一种新的全身肿瘤负荷视觉分类方案(MDT方案:高负荷 vs 低负荷),并评估其对激素治疗PSA反应的预测和预后价值。多因素分析显示MDT方案高负荷组较低负荷组PSA反应OR=5.34(95%CI 2.40-11.87,P<0.001),是独立预测因子;在ADT+第二代ARSIs亚组(N=133)中OR=5.73(95%CI 2.47-13.30,P<0.001)。MDT方案亦是独立预后指标(HR=0.52,95%CI 0.36-0.74,P<0.001)。

要点

  • MDT高负荷组较低负荷组PSA反应OR=5.34(95%CI 2.40-11.87,P<0.001),为独立预测因子。
  • ADT+第二代ARSIs亚组中MDT高负荷组PSA反应OR=5.73(95%CI 2.47-13.30,P<0.001)。
  • MDT方案高负荷组较低负荷组PSA99预后HR=0.52(95%CI 0.36-0.74,P<0.001)。

核心结论

  • 基于PSMA PET/CT的全身肿瘤负荷视觉分类可能是接受ADT+ARSIs(尤其是ADT+第二代ARSIs)的mHSPC患者的有效分层策略。
  • PSA99(PSA下降≥99%)可能是HSPC患者更优的终点指标。
  • 该分类方案可能是对mHSPC患者进行分层的有前景的方法。
  • 这些发现需要通过更长的随访、前瞻性及临床数据进一步确认和验证。

研究设计与样本

  • 纳入2022年2月至2023年12月在本院经病理和[18F]F-PSMA PET/CT诊断为初诊mHSPC并接受ADT单药或ADT联合第一代抗雄激素或ADT联合第二代/新型ARSIs的患者。
  • 要求初诊后至少六个月方可采用激素治疗(ADT或ADT联合第一代抗雄激素或ADT联合新型ARSIs)。
  • 本院前列腺癌多学科团队(MDT)提出基于PSMA PET/CT的新视觉全身肿瘤负荷方案(MDT方案:高负荷 vs 低负荷)。
  • 同时评估其他三种肿瘤负荷分类方法(PSMA-CHAARTED、PSMA-LATITUDE、修订版vPSG方案)。
  • 评估PSMA PET/CT的SUV衍生特征及潜在临床病理因素,采用logistic和Cox比例风险回归分析预测和预后价值。

主要发现

  • 共纳入165例患者,平均年龄69.30±8.12岁。
  • 单因素logistic回归中,MDT、PSMA-CHAARTED、修订版vPSG肿瘤负荷分类、激素治疗类型和原发灶TV与PSA反应显著相关,PSMA-LATITUDE方案与PSA反应无关。
  • 多因素logistic回归显示MDT方案(高负荷组 vs 低负荷组:OR=5.34,95%CI 2.40-11.87,P<0.001)、激素治疗类型(ADT+第二代ARSIs vs ADT单药或ADT+第一代抗雄激素:OR=0.21,95%CI 0.08-0.53,P=0.001)和原发灶TV(≥12.49 cm3 vs <12.49 cm3:OR=2.93,95%CI 1.25-6.89,P=0.014)为独立显著预测因子。
  • ADT+第二代ARSIs亚组(N=133)多因素回归中,MDT方案(高负荷组 vs 低负荷组:OR=5.73,95%CI 2.47-13.30,P<0.001)和原发灶TV(≥12.49 cm3 vs <12.49 cm3:OR=2.75,95%CI 1.09-6.96,P=0.032)为PSA反应的独立显著预测因子。
  • 165例mHSPC患者三预测因子模型AUC为0.740(95%CI 0.664-0.816,P<0.001);133例接受ADT+新型ARSIs患者两预测因子模型AUC为0.751(95%CI 0.666-0.836,P<0.001)。

关键数值与推荐

  • MDT高负荷组需满足以下三项标准中任意一项:(I)转移病灶数超过10个(单一骨弥漫受累计为4个病灶)且80%病灶的PSMA摄取水平高于腮腺;(II)存在内脏转移;(III)至少4处骨转移(≥1处超出椎体或骨盆)。
  • 主要终点:六个月激素治疗后血清PSA低于0.2 ng/ml,用于预测PSA反应。
  • 次要终点:PSA99(PSA下降≥99%),用于生存分析。
  • 所有P值<0.05认为显著。
  • 多因素Cox回归中,MDT方案(高负荷组 vs 低负荷组:HR=0.52,95%CI 0.36-0.74,P<0.001)和激素治疗类型(ADT+第二代ARSIs vs ADT单药或ADT+第一代抗雄激素:HR=3.34,95%CI 2.02-5.54,P<0.001)为独立显著预后指标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些发现需要通过更长的随访、前瞻性及临床数据进一步确认和验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The incidence rates of metastatic hormone-sensitive prostate cancer (mHSPC) have increased rapidly. Androgen deprivation therapy (ADT) with AR signaling inhibitors (ARSIs) has been determined survival benefit for mHSPC patients in several randomized trials. However, patients do not respond uniformly. Whole-body tumor-burden schemes guided by prostate-specific membrane antigen (PSMA) PET/CT have been proven to be a useful predictive tool for PSMA-targeted radioligand therapy (RLT), while the value for hormone therapy was unclear. We hypothesized a visual whole-body tumor-burden classification based on PSMA PET/CT can enable selective patient stratification and prognostic evaluation for hormone treatment. MATERIALS AND METHODS: Patients diagnosed with de novo mHSPC through pathological test and [18F]F-PSMA PET/CT between February 2022 and December 2023 who received ADT alone or ADT plus first-generation antiandrogens or ADT plus second-generation/novel ARSIs in our hospital were included. Only can hormone treatments (ADT or ADT plus first-generation antiandrogens or ADT plus novel ARSIs) be adopted at least six months after initial diagnosis. Prostate Cancer Multidisciplinary Team (MDT) of our hospital proposed a newly visual whole-body tumor-burden scheme based on PSMA PET/CT (MDT scheme: high vs. low): MDT high group (fulfilling any one of the three following criteria): (I) the number of metastatic lesions is more than 10 (diffused involvement of single bone is counted as 4 lesions) and PSMA uptake levels of 80% lesions are higher than that of parotid glands, (II) the presence of visceral metastases, (III) at least 4 bone metastases (≥ 1 beyond the vertebral bodies or the pelvis). In addition, other three tumor-burden classification methods (PSMA-CHAARTED, PSMA-LATITUDE, revised-vPSG schemes) were also assessed in this study. A series of other parameters including SUV-derived features of PSMA PET/CT and potential clinical and pathological factors were evaluated. SUV-derived features were determined for measurable locations and included: SUVmax, SUVpeak, SUVmean and tumor volume (TV) of prostatic primary lesions, the highest SUVmax of all lesions in whole body (wbSUVmax), primary-tumor SUVmax ratio backgrounds (including blood pool of liver/ spleen/ mediastinum/parotid glands), wbSUVmax ratio backgrounds above. Serum prostate-specific antigen (PSA) lower than 0.2 ng/ml after six-month hormone treatment was set as the primary endpoint for prediction of PSA response. PSA99 (PSA reduction ≥ 99%) was the second endpoint for survival analysis. All parameters above including the four tumor-burden classification schemes were evaluated for the predictive and prognostic value according to the endpoints using logistic and Cox proportional hazards regression analysis, respectively. All P values < 0.05 were considered significant. RESULTS: A total of 165 patients were included. The average age was 69.30 ± 8.12 years. In univariate logistic regression analysis, MDT, PSMA-CHAARTED, revised-vPSG tumor-burden classifications, type of hormone treatment and primary-tumor TV were significantly related to PSA response, and PSMA-LATITUDE scheme wasn't relevant to PSA response. The results of further multivariate logistic regression revealed MDT scheme (MDT high group vs. low group: OR = 5.34, 95%CI: 2.40-11.87, P < 0.001), type of hormone treatment (ADT + second-generation ARSIs vs. ADT alone or ADT + first-generation antiandrogens: OR = 0.21, 95%CI: 0.08-0.53, P = 0.001), and primary-tumor TV (≥ 12.49 cm3 vs. < 12.49 cm3: OR = 2.93, 95%CI: 1.25-6.89, P = 0.014) were proven to be independent significant predictors for mHSPC patients. Subgroups analysis of patients treated with ADT + second-generation ARSIs (N = 133) showed MDT, PSMA-CHAARTED, PSMA-LATITUDE, revised-vPSG tumor-burden classifications and primary-tumor TV were significantly associated with PSA response through univariate analysis, and in multivariate regression MDT scheme (MDT high group vs. low group: OR = 5.73, 95%CI: 2.47-13.30, P < 0.001) and primary-tumor TV (≥ 12.49 cm3 vs. < 12.49 cm3: OR = 2.75, 95%CI: 1.09-6.96, P = 0.032) were independent significant predictors for PSA response of novel ARSIs. The AUC of three-predictors model of 165 mHSPC patients was 0.740 (95% CI: 0.664-0.816, P < 0.001). The AUC of two-predictors model of 133 mHSPC patients treated with ADT + novel ARSIs was 0.751 (95% CI: 0.666-0.836, P < 0.001). Univariate survival analysis revealed that patients treated with ADT + second-generation ARSIs were prone to obtaining PSA remission in shorter period (P < 0.001). In multivariate Cox regression, MDT scheme (MDT high group vs. low group: HR = 0.52, 95%CI: 0.36-0.74, P < 0.001) and type of hormone treatment (ADT + second-generation ARSIs vs. ADT alone or ADT + first-generation antiandrogens: HR = 3.34, 95%CI: 2.02-5.54, P < 0.001) were demonstrated to be independent significant prognostic indicators of patients with mHSPC. The survival analysis of patients treated with ADT + second-generation ARSIs (N = 133), patients with low burden of MDT (P < 0.001) or PSMA-CHAARTED (P = 0.029) or PSMA-LATITUDE (P = 0.009) could achieve PSA 99% reduction faster, and the low and high group patients based on revised-vPGS weren't displayed the significant difference in PSA99. Through the multivariate Cox survival regression, only MDT scheme (MDT high group vs. low group: HR = 0.47, 95%CI: 0.33-0.69, P < 0.001) was selected as the independent significant prognostic biomarker for mHSPC patients treated with ADT + second-generation ARSIs. CONCLUSION: The visual whole-body tumor-burden classification based on PSMA PET/CT should be an effective stratification strategy for mHSPC patients treated with ADT + ARSIs, especially with ADT + second-generation ARSIs. PSA99 (PSA reduction ≥ 99%) could be a superior endpoint for patients with HSPC. This classification scheme could be a promising method for stratifying mHSPC patients. These findings need to be confirmed and validated through a longer follow-up, prospective and clinical data.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liao X, Li S, Sun H, et al. A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients. Eur J Nucl Med Mol Imaging. 2025. PMID: 40278858. doi:10.1007/s00259-025-07300-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。